Table 3.
CRP haplotype build, frequency and effect on serum C-reactive protein and Disease Activity Score in 28 joints at baseline and year 1 a
| Haplotype | Frequency | Baseline CRP, effect (CI) | Year 1 CRP, effect (CI) | Baseline DAS28, effect (CI) | Year 1 DAS28, effect (CI) |
|---|---|---|---|---|---|
| H1 (CACT) | 30.5% | 96% (73 to 126) | 99% (77 to 126) | 102% (98 to 107) | 105% (97 to 113) |
| H2 (TGCT) | 25.7% | 74% (55 to 99) | 91% (70 to 118) | 99% (94 to 103) | 97% (89 to 106) |
| H3 (CGCG) | 31.4% | 100% | 100% | 100% | 100% |
| H4 (CGCT) | 6.2% | 66% (41 to 107) | 121% (80 to 184) | 95% (88 to 103) | 102% (89 to 116) |
| H5 (TGGT) | 5.5% | 64% (40 to 103) | 86% (56 to 134) | 101% (93 to 108) | 110% (95 to 124) |
Haplotype defining SNPs = (rs1205, rs1130864, rs1800947, rs2808632). The effects of each haplotype were given relative to the most frequent haplotype, which was used as reference. CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; SNP, Single-nucleotide polymorphism.